Comments

;

Public Comments on Potential Viral Hepatitis Quality Measures in Medicaid

Jun 7, 2024

We support the adoption of quality measures for hepatitis B and hepatitis C in Medicaid. We support the adoption of hepatitis C screening and treatment initiation measures within state Medicaid programs. We urge HHS to consider quality measures for hepatitis B screening and linkage to care, as well as for hepatitis C sustained virological response (SVR) for testing and proposal to the Medicaid Adult Core Set. We support the implementation of hepatitis B screening, hepatitis C screening, and hepatitis C treatment initiation quality measures within state Medicaid programs.

read more

Comments to MD Prescription Drug Affordability Board on HIV treatments

May 15, 2024

While we are supportive of the Maryland Prescription Drug Affordability Board (PDAB) goal of improving treatment affordability, we urge PDAB members and staff to address concerns surrounding access to provider-recommended HIV treatments at the individual level and the impact on broader public health goals and provide clarity around the affordability review process to enable meaningful community input.

read more

Support for changing the NV essential health benefits benchmark plan

Apr 12, 2024

We support changing the state EHB benchmark plan to one that covers all FDA-approved tests and drugs to treat and prevent HIV, hepatitis B, hepatitis C, and opioid use. It is a timely juncture for states that wish to improve access to testing, treatment, and prevention for HIV and viral hepatitis to consider an update to a more generous EHB benchmark plan.  The recently finalized 2025 Notice of Benefit and Payment Parameters has created new opportunities for states to define what comprehensive health insurance should look like and to close gaps in coverage.

read more

Comments on ERISA’s 50th anniversary–reforms to increase affordability and quality in employer-sponsored health coverage

Mar 15, 2024

Employer-sponsored insurance is the most common form of health insurance in the United States, covering over 60 percent of the population under 65.[1]  As we detail below, many employers have begun to create new health insurance barriers that prevent employees and their family members from accessing the medications they need to stay alive and healthy.  Our comments focus on certain novel benefit designs that have become more prevalent in recent years among employer-sponsored insurance plans: copay accumulators, copay maximizers, and alternative funding programs, as well as the practice of skirting ACA requirements by designating certain specialty medications as non-Essential Health Benefits.

read more

Comments in support of New Hampshire SB 354

Jan 23, 2024

It is a pleasure to voice our strong support for Senate Bill 354-FN (“relative to insurance cost-sharing calculations”) which would require health insurers and pharmacy benefit managers to include any amount paid by the enrollee or on their behalf in calculating an enrollee’s contribution to cost-sharing requirements. We thank you for holding a hearing on this important issue and ask that you consider and pass the bill.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest